Claritin patent hearing
This article was originally published in The Tan Sheet
Federal Circuit Court of Appeals will hear oral arguments April 8 in Schering-Plough's appeal of lower court ruling that its desloratadine patents are invalid. New Jersey federal judge ruled in August that Schering cannot rely on patent claims covering desloratadine (Clarinex) to keep generic versions of Claritin off the OTC market before 2004 (1"The Tan Sheet" Aug. 12, 2002, p. 3)...
You may also be interested in...
Schering-Plough will not be able to rely on patent claims covering desloratadine to keep generic versions of its Claritin antihistamine off the OTC market before 2004 if a federal judge's ruling is upheld on appeal
iTeos presents early anti-TIGIT results, Affimed reports 100% response rate in Hodgkin lymphoma, Treovir will start a pivotal Phase II after Phase I pediatric glioma study, updates in KRAS-mutated cancers from Revolution Medicines and Cardiff Oncology, plus Opdivo plus chemo shows complete responses in neoadjuvant lung cancer and Lilly’s Retevmo is active in additional tumors.
India stops remdesivir exports amid steep surge in COVID-19 cases, while licensees of Gilead’s antiviral progress multiple measures to ramp up production to meet local demand. One badly affected state stresses the need to stem panic given the limitations of the treatment, even as some non-licensees of the drug apparently seek to contribute to supplies.